Indivior Pharmaceuticals, Inc.
INDV· Nasdaq
INDVIndivior Pharmaceuticals, Inc.
Quarterly figures for Indivior Pharmaceuticals, Inc., with source filings when available.
10 quarters. Mar 31, 2024 to Jun 30, 2026. USD.
Indivior Pharmaceuticals, Inc. has filed its 10-Q within 30 to 34 days of period end across its last 5 quarters. The 10-K runs 57 to 62 days.
Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Source trail |
|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | |||||||||
| Q2 2026 | Jun 30, 2026 | Aug 3, 2026 · pre-market | Aug 3, 2026 | 34 d | 10-Q | $343.00M | +13.6% | $0.98 | |
| Q1 2026 | Mar 31, 2026 | Apr 30, 2026 · pre-market | Apr 30, 2026 | 30 d | 10-Q | ||||
| FY 2025 | |||||||||
| Q4 2025derived | Dec 31, 2025 | Feb 26, 2026 · pre-market | Feb 26, 2026 | 57 d | 10-K | $357.00M | +19.8% | — | |
| Q3 2025 | Sep 30, 2025 | Oct 30, 2025 · pre-market | Oct 30, 2025 | ||||||
| FY 2024 | |||||||||
| Q4 2024 | Dec 31, 2024 | — | Mar 3, 2025 | 62 d | 10-K | $298.00M | — | — | |
| Q3 2024 | Sep 30, 2024 | — | — | — | |||||
| $317.00M |
| +19.2% |
| $0.69 |
| 30 d |
| 10-Q |
| $314.00M |
| +2.3% |
| $0.33 |
| Q2 2025 | Jun 30, 2025 | Jul 31, 2025 · pre-market | Jul 31, 2025 | 31 d | 10-Q | $302.00M | +1.0% | $0.14 |
|---|
| Q1 2025 | Mar 31, 2025 | Apr 23, 2025 · after-hours | May 1, 2025 | 31 d | 10-Q | $266.00M | −6.3% | $0.38 |
|---|
| — |
| $307.00M |
| — |
| $0.16 |
| Q2 2024 | Jun 30, 2024 | — | — | — | — | $299.00M | — | -$0.72 |
|---|
| Q1 2024 | Mar 31, 2024 | — | — | — | — | $284.00M | — | $0.45 |
|---|
